Evidence map›Paper›PMID 40968392›Full record

ReviewCancer science2025

Microbial and Metabolic Disorders in Cervical Cancer: Structural Insights, Biomarkers, Mechanisms, and Therapeutic Strategies.

Hong Tao, Luyu Wang, Yi Ding, Lixian Yi, Mutian Han, Mengmeng Gu, Jian Wu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hong TaoJiangsu Province Engineering Research Center of Development and Translation of Key Technologies for Chronic Disease Prevention and Control, Suzhou Vocational Health College, Suzhou, China.
Luyu WangAnhui Province Key Laboratory of Immunology in Chronic Diseases, Research Center of Laboratory, School of Laboratory, Bengbu Medical University, Bengbu, China.
Yi DingJiangsu Province Engineering Research Center of Development and Translation of Key Technologies for Chronic Disease Prevention and Control, Suzhou Vocational Health College, Suzhou, China.
Lixian YiJiangsu Province Engineering Research Center of Development and Translation of Key Technologies for Chronic Disease Prevention and Control, Suzhou Vocational Health College, Suzhou, China.
Mutian HanDepartment of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China.
Mengmeng GuDepartment of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China.
Jian WuDepartment of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China.ORCID https://orcid.org/0000-0003-0087-3744

Funding

Gusu Health Talent Program Research Project GSWS2023004Jiangsu Province Engineering Research Center of Development and Translation of Key Technologies for Chronic Disease Prevention and Control CDSGK1202501Suzhou Science, Education and Health Promotion General Program MSXM2024021
6 · The paper itself

Abstract

The development of cervical cancer is strongly associated with persistent high-risk HPV infection. Microbiota and metabolomics offer new perspectives. This article focuses on the role of microbial dysbiosis and metabolic reprogramming in the development of cervical cancer, revealing its synergistic regulation of the tumor immune microenvironment and treatment resistance. Machine learning and multi-omics have identified new biomarkers, while treatment strategies include microbiota modulation, metabolic targeting, and combination therapies. Despite limitations such as small sample size and unclear mechanisms, this review proposes a multi-target precision medicine framework. In the future, we should focus on multi-center and multi-omics research and optimized clinical trials.

Indexed as

DysbiosisMetabolic DiseasesUterine Cervical NeoplasmsBiomarkers, TumorFemaleHumansMetabolomicsMicrobiotaPapillomavirus InfectionsPrecision MedicineTumor MicroenvironmentBiomarkers, Tumorcervical cancerFMTmetabolomicsmicrobiotaprecision medicine

Identifiers

PMID40968392
PMCPMC12666474

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.